← All trials
NCT04582201
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2020
- Primary completion
- Apr 24, 2021
- Completion date
- Oct 15, 2021
- First posted
- Oct 9, 2020
- Last posted
- Oct 29, 2020
- Enrollment
- 55
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MiNK TherapeuticsLead sponsor
- Agenus Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.